Top Page
Evaxion Biotech
(NASDAQ:EVAX)
Evaxion Biotech (EVAX) vs. SPDR S&P 500 ETF (SPY)
Evaxion Biotech Business Overview & Revenue Model
Evaxion Biotech Earnings Call Summary
Evaxion Biotech Financial Statement Overview
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.55M | 3.34M | 73.00K | 0.00 | 0.00 |
| Gross Profit | 0.00 | 3.34M | 73.00K | 0.00 | 0.00 |
| EBITDA | -8.65M | -9.79M | -21.40M | -22.57M | -24.21M |
| Net Income | -7.73M | -10.57M | -22.13M | -23.17M | -24.53M |
Balance Sheet | |||||
| Total Assets | 28.41M | 12.48M | 12.89M | 22.02M | 40.16M |
| Cash, Cash Equivalents and Short-Term Investments | 23.23M | 5.05M | 4.18M | 13.18M | 32.17M |
| Total Debt | 7.50M | 10.10M | 10.87M | 10.26M | 3.69M |
| Total Liabilities | 11.37M | 14.14M | 17.62M | 13.72M | 7.73M |
| Stockholders Equity | 17.04M | -1.65M | -4.73M | 8.30M | 32.44M |
Cash Flow | |||||
| Free Cash Flow | -6.66M | -12.94M | -17.78M | -26.07M | -23.29M |
| Operating Cash Flow | -6.65M | -12.94M | -17.69M | -25.77M | -21.93M |
| Investing Cash Flow | -14.04K | -3.00K | -93.00K | -268.00K | -1.33M |
| Financing Cash Flow | 22.48M | 13.13M | 10.69M | 7.85M | 49.80M |
Evaxion Biotech Technical Analysis
Evaxion Biotech Risk Analysis
Evaxion Biotech Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $31.86M | -3.95 | -61.62% | ― | 4455.07% | 77.31% | |
56 Neutral | $92.17M | 0.18 | ― | ― | ― | 49.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $43.17M | 0.54 | -225.83% | ― | -14.92% | 72.81% | |
48 Neutral | $75.10M | -3.58 | -3071.15% | ― | 36.89% | 43.58% | |
47 Neutral | $26.80M | -5.18 | -96.36% | ― | -6.51% | 58.31% | |
47 Neutral | $105.99M | -2.74 | 252.30% | ― | 234.73% | 81.16% |
Evaxion Biotech Corporate Events
On March 5, 2026, Evaxion reported that 2025 was a transformational year marked by strategic, scientific and financial advances, including a historic licensing deal with MSD for its infectious disease vaccine candidate EVX-B3 and strong two-year phase 2 data for its personalized melanoma vaccine EVX-01. The company also expanded its pipeline with the AML vaccine EVX-04 and Group A Streptococcus candidate EVX-B4, entered a polio collaboration with the Gates Foundation, won a Galien Foundation award for AI-Immunology and strengthened its balance sheet by more than $30 million and a debt conversion with the EIB, leaving it funded into the second half of 2027 and positioning it to pursue 2026 milestones in oncology, infectious diseases and autoimmune applications of its platform while maintaining an annual cash burn of about $14 million.
Evaxion plans in 2026 to launch a new AI-Immunology application for autoimmune diseases, deepen the clinical dataset for EVX-01 with biomarker, immunogenicity and three-year efficacy results and file for a phase 1 trial of EVX-04 in AML, alongside key preclinical validation steps for the EVX-B4 strep vaccine. Clinical and preclinical data presented in 2025 at major conferences for EVX-01, EVX-04 and the CMV program EVX-V1 underscored the platform’s ability to discover highly immunogenic, novel antigens, reinforcing Evaxion’s partnering appeal as it pursues additional platform and pipeline deals under tight cost control.
The most recent analyst rating on (EVAX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
On March 5, 2026, Evaxion A/S reported a brief technical delay in filing and publishing its 2025 annual report, which had been scheduled before the opening of the Nasdaq Capital Market that day. The company emphasized that the report itself was finalized as planned and that the issue stemmed from external vendors handling regulatory filing requirements, rather than from any underlying financial or operational problems.
As a result of the filing delay, Evaxion rescheduled its planned conference call and webcast from March 5 to March 6, 2026, while maintaining the same format for investor access via phone and webcast. The minor postponement highlights the company’s reliance on third-party vendors for regulatory processes but does not appear to signal any change in business fundamentals, limiting the immediate impact for shareholders and other stakeholders to a short-term shift in the investor communications timetable.
The most recent analyst rating on (EVAX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Evaxion A/S, a clinical-stage TechBio company listed on Nasdaq and focused on AI-driven cancer and infectious disease vaccines, announced that it will deliver a business update alongside its full-year 2025 financial results on March 5, 2026. The company’s leadership will host a conference call and webcast that day before the U.S. market opens, underscoring its efforts to engage investors and other stakeholders as it progresses its AI-Immunology-powered vaccine pipeline and broader corporate strategy.
The most recent analyst rating on (EVAX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
On February 5, 2026, Evaxion Biotech’s board granted 6,544,725 warrants to directors, management and employees, with most vesting monthly from January 1, 2026, and a portion fully vested at grant, at an exercise price set in USD and converted to DKK with a floor of DKK 0.25 per share. Following this issuance, the company amended its Articles of Association and left capacity for additional warrants corresponding to a nominal DKK 7,482,257 in ordinary shares.
On February 16, 2026, the board approved a further 2,500,000 warrants to board members, management, staff and advisers, vesting monthly from November 1, 2025, at a higher USD-based exercise price subject to the same DKK 0.25 floor. After this second grant and related amendments to the Articles, Evaxion retained authority to issue more warrants for up to a nominal DKK 6,857,257 in shares, underscoring its continued reliance on equity-based incentives and potential future dilution for existing shareholders.
The most recent analyst rating on (EVAX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
On January 13, 2026, Evaxion A/S announced that it is expanding its AI-Immunology platform into autoimmune diseases, adding this as a third core therapeutic area alongside cancer and infectious diseases. The move is intended to leverage the scalability of its AI technology to generate a broader and higher-quality pipeline of precision treatments that address underlying disease mechanisms rather than just symptoms, thereby enhancing the company’s partnership potential across all stages of drug development. Evaxion stated that the training of AI-Immunology for autoimmune applications is planned for the second half of 2026 and that this work is already incorporated into its financial plans, with its cash runway still expected to extend into the second half of 2027. The company also outlined key 2026 milestones, including additional biomarker and immunogenicity data and three-year Phase 2 efficacy data for EVX-01, a regulatory filing for a Phase 1 trial of EVX-04, a preclinical antigen design milestone for EVX-B4, and the launch of the new autoimmune application, underscoring continued execution of its strategy to create value from both its platform and pipeline assets through partnerships.
The most recent analyst rating on (EVAX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
On January 7, 2026, Evaxion A/S announced that it will present its 2026 company milestones and provide a corporate update at the Biotech Showcase conference in San Francisco, held January 12-14, 2026. Chief executive Helen Tayton-Martin is scheduled to speak on January 13, 2026, with Evaxion also planning broader engagement with potential business partners and other stakeholders during the week, coinciding with the high-profile J.P. Morgan Healthcare Conference, which could enhance the company’s visibility and partnering prospects in the biotech and life sciences investment community.
The most recent analyst rating on (EVAX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
On December 19, 2025, Evaxion A/S reported that its collaboration partner MSD chose not to exercise an option to develop Evaxion’s gonorrhea vaccine candidate EVX-B2, leaving Evaxion with global rights and the ability to seek a new licensing partner for the asset. The company emphasized that preclinical data show EVX-B2 protects against gonorrhea, a disease affecting more than 80 million people annually with no approved vaccine, and noted that MSD’s decision does not affect Evaxion’s cash runway, which it says still extends into the second half of 2027; Evaxion also continues its separate mRNA-based EVX-B2 program with Afrigen Biologics and retains potential milestone and royalty upside from MSD’s earlier exercise of an option on a different vaccine candidate, EVX-B3.
The most recent analyst rating on (EVAX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.